New developments in the treatment of deep venous thrombosis

Autor: M.C.H. Janssen, H.C.H. Wollersheim, Irena Novakova, Th. Thien, H.W. Verbruggen
Jazyk: angličtina
Rok vydání: 1997
Předmět:
medicine.medical_specialty
medicine.drug_class
Deep vein
Low molecular weight heparin
diagnostiek
behandeling en preventie van de late gevolgen [Diepe veneuze trombose]
Pharmacotherapy
Internal Medicine
medicine
Humans
Thrombolytic Therapy
GeneralLiterature_REFERENCE(e.g.
dictionaries
encyclopedias
glossaries)
Prothrombin time
Dose-Response Relationship
Drug
medicine.diagnostic_test
business.industry
Drug Administration Routes
Anticoagulant
Anticoagulants
Heparin
Thrombophlebitis
medicine.disease
Thrombosis
Surgery
Tromboembolische complicaties bij patienten met maligniteiten
Venous thrombosis
medicine.anatomical_structure
Anesthesia
diagnostic and therapeutic aspects and the prevention of the consequences at long-term [Deep venous thrombosis]
Thromboembolic complications in patients with malignancies
Prothrombin Time
Drug Therapy
Combination
business
medicine.drug
Zdroj: Netherlands Journal of Medicine, 50, 36-45
Netherlands Journal of Medicine, 50, 1, pp. 36-45
ISSN: 0300-2977
Popis: An initial course of standard heparin (SH) or low-molecular-weight heparins (LMWH) is regarded as the treatment of choice for patients with deep venous thrombosis (DVT). LMWH have better bioavailability after subcutaneous administration, have a longer half-life, and show higher and more predictable anticoagulant activity. As a result they can be given subcutaneously and without laboratory control, using a dose that is determined by bodyweight. Because of these multiple advantages of LMWH they will replace SH in the future and subsequently home treatment with LMWH of selected patients seems feasible. The currently accepted approach is to start with SH or LMWH therapy combined with oral anticoagulant therapy. (OAT) at the time of diagnosis. The course of SH or LMWH should continue for at least 5 days, provided that international normalized ratio (INR) is in the therapeutic range on 2 consecutive days. OAT should be continued for at least 3 months to prolong the prothrombin time to an INR of 2-3. When oral anticoagulants are either contraindicated or inconvenient, SH or LMWH can be used at the middosing interval. The role of anti-platelet treatment is not yet established and should be compared with coumarin therapy in the future.
Databáze: OpenAIRE
Externí odkaz: